Pfizer, Lilly Weigh In On Dosing And Safety Of Non-Opioid Pain Drug Tanezumab
Executive Summary
Two dosing regimens hit the mark on three co-primary endpoints and the rate of rapidly progressive osteoarthritis was low at 1.3% in a Phase III study of the NGF inhibitor presented on Oct. 23.